Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice

  • Afonso-Cardoso, Sandra R. (Laboratorio de Biologia Molecular, Instituto de Ciencias Biomedicas,Universidade Federal de Uberlandia) ;
  • Rodrigues, Flavio H. (Laboratorio de Biologia Molecular, Instituto de Ciencias Biomedicas,Universidade Federal de Uberlandia) ;
  • Gomes, Marcio A.B. (Laboratorio de Biologia Molecular, Instituto de Ciencias Biomedicas,Universidade Federal de Uberlandia) ;
  • Silva, Adriano G. (Laboratorio de Imunologia Celular e Humoral do Instituto Oswaldo Cruz) ;
  • Rocha, Ademir (Laboratorio de Patologia, Universidade Federal de Uberlandia) ;
  • Guimaraes, Aparecida H.B. (Laboratorio de Patologia, Universidade Federal de Uberlandia) ;
  • Candeloro, Ignes (Laboratorio de Patologia, Universidade Federal de Uberlandia) ;
  • Favoreto, Silvio (Northwestern University Feinberg School of Medicine) ;
  • Ferreira, Marcelo S. (Servico de Infectologia, Hospital de Clinicas, Universidade Federal de Uberlandia) ;
  • Souza, Maria A. de (Laboratorio de Biologia Molecular, Instituto de Ciencias Biomedicas, Universidade Federal de Uberlandia)
  • Published : 2007.12.31

Abstract

The protective effect of the Synadenium carinatum latex lectin (ScLL), and the possibility of using it as an adjuvant in murine model of vaccination against American cutaneous leishmaniasis, were evaluated. BALB/c mice were immunized with the lectin ScLL (10, 50, 100$[\mu}g$/animal) separately or in association with the soluble Leishmania amazonensis antigen (SLA). After a challenge infection with $10^6$ promastigotes, the injury progression was monitored weekly by measuring the footpad swelling for 10 weeks. ScLL appeared to be capable of conferring partial protection to the animals, being most evident when ScLL was used in concentrations of 50 and 100${\mu}g$/animal. Also the parasite load in the interior of macrophages showed significant reduction (61.7%) when compared to the control group. With regard to the cellular response, ScLL 50 and 100 ${\mu}g$/animal stimulated the delayed-type hypersensitivity (DTH) reaction significantly (P < 0.05) higher than SLA or SLA plus ScLL 10 weeks after the challenge infection. The detection of high levels of IgG2a and the expression of mRNA cytokines, such as IFN-$\gamma$, IL-12, and TNF-$\alpha$ (Th1 profiles), corroborated the protective role of this lectin against cutaneous leishmaniasis. This is the first report of the ScLL effect on leishmaniasis and shows a promising role for ScLL to be explored in other experimental models for treatment of leishmaniasis.

Keywords

References

  1. Alexander J, Bryson K (2005) T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 99: 17-23 https://doi.org/10.1016/j.imlet.2005.01.009
  2. Andrade ZA, Reed SG, Roters SB, Sadigursky M (1984) Immunopathology of experimental cutaneous leishmaniasis. Am J Pathol 114: 137-148
  3. Barral-Netto M, Cheever AW, Lawley TJ, Ottesen EA (1983) Cell-mediated and humoral immune responses in capuchin monkeys infected with Schistosoma japonicum or Schistosoma mansoni. Am J Trop Med Hyg 32: 1335- 1343 https://doi.org/10.4269/ajtmh.1983.32.1335
  4. Barral-Netto M, de Freitas LAR, Andrade ZA (1987) Histopathologic changes induced by vaccination in experimental cutaneous leishmaniasis of BALB/c mice. Am J Pathol 127: 271-278
  5. Barral-Netto M, von Sohsten RL, Teixeira M, dos Santos WLC, Pompeu ML, Moreira RA, Oliveira JT, Cavada BS, Falcoff E, Barral A (1996) In vivo protective effect of the lectin from Canavalia brasiliensis on BALB/c mice infected by Leishmania amazonensis. Acta Trop 60: 237-250 https://doi.org/10.1016/0001-706X(95)00120-4
  6. Cardoso SR, da Silva JCF, da Costa RT, Mayrink W, Melo MN, Michalick MSV, Liu IAW, Fujiwara RT, Nascimento E (2003) Identification and purification of immunogenic proteins from nonliving promastigote polyvalent Leishmania vaccine (Leishvacin). Rev Soc Bras Med Trop 36: 193-199 https://doi.org/10.1590/S0037-86822003000200001
  7. Deplazes P, Smith NC, Arnold P, Lutz H, Eckert J (1995) Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 17: 451-458 https://doi.org/10.1111/j.1365-3024.1995.tb00914.x
  8. Elvin-Lewis M (2001) Should we be concerned about herbal remedies? J Ethnopharmacol 75: 141-164 https://doi.org/10.1016/S0378-8741(00)00394-9
  9. Guimaraes ET, Santos LA, dos Santos RR, Teixeira MM, dos Santos WLC, Soares MBP (2006) Role of inertelukin-4 prostaglandin E2 in Leishmania amazonensis infection of BALB/c. Microbes Infect 8: 1219-1226 https://doi.org/10.1016/j.micinf.2005.11.011
  10. Hernandez MXS, Barcante TA, Vilela L, Tafuri WL, Afonso LCC, Vieira LQ (2006) Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40. Immunol Lett 105: 38-47 https://doi.org/10.1016/j.imlet.2005.12.002
  11. Ivory C, Chadee K (2004) DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2: 17 https://doi.org/10.1186/1479-0556-2-17
  12. Kaye PM, Curry AJ, Blackwell JM (1991) Differential production of Th1 and Th2 derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine leishmaniasis. J Immunol 146: 2763-2770
  13. Liew FY, O'Donnell CA (1993) Immunology of leishmaniasis. Adv Parasitol 32: 161-259 https://doi.org/10.1016/S0065-308X(08)60208-0
  14. Liew FY, Hale C, Howard JG (1985) Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J Immunol 135: 2095-2101
  15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275
  16. Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber F, Mayrink W (2002) Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonials. Int J Dermatol 41: 73-78 https://doi.org/10.1046/j.1365-4362.2002.01336.x
  17. Marques-da-Silva EA, Coelho EAF, Gomes DCO, Vilela MC, Masioli CZ, Tavares CAP, Fernandes AP, Afonso LCC, Rezende SA (2005) Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-$\gamma$ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol Res 98: 67-74 https://doi.org/10.1007/s00436-005-0008-8
  18. Mohammadi MR, Zeinali M, Ardestani SK, Kariminia A (2006) Identification of novel Leishmania major antigens that elicit IgG2a response in resistant and susceptible mice. Korean J Parasitol 44: 43-48 https://doi.org/10.3347/kjp.2006.44.1.43
  19. Moingeon P, Haensler J, Lindberg A (2001) Towards the rational design of Th1 adjuvants. Vaccine 19: 4363-4372 https://doi.org/10.1016/S0264-410X(01)00193-1
  20. Oliveira-Freitas E, Casas CP, Borja-Cabrera GP, Santos FN, Nico D, Souza LOP, Tinoco LW, da Silva BP, Palatnik M, Parente JP, Palatnik-de-Sousa CB (2006) Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 24: 3909-3920 https://doi.org/10.1016/j.vaccine.2006.02.034
  21. Palatnik de Sousa CB, Santos WR, Casas CP, Paraguai de Souza E, Tinoco LW, da Silva BP, Palatnik M, Parente JP (2004) Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins. Vaccine 22: 2470-2479 https://doi.org/10.1016/j.vaccine.2004.01.072
  22. Panunto-Castelo A, Souza MA, Roque-Barreira MC, Silva JS (2001) $KM^{+}$, a lectin from Artocarpus integrifolia, induces IL-12p40 production by macrophages and switches from type 2 to type 1 cell mediated immunity against L. major antigens, resulting in BALB/c mice resistance to infection. Glycobiology 11: 1035-1042 https://doi.org/10.1093/glycob/11.12.1035
  23. Peumans WJ, van Damme EJ (1995) The role of lectins in plant defense. Histochem J 27: 253-271 https://doi.org/10.1007/BF00398968
  24. Rogerio AP, Cardoso CR, Fontanari C, Souza MA, Afonso- Cardoso SR, Silva EVG, Koyama NS, Basei FL, Soares EG, Calixto JB, Stowell SR, Dias-Baruffi M, Faccioli LH (2007) Anti-asthmatic potential of a D-galactose-binding lectin from Synadenium carinatum latex. Glycobiology 17: 795-804 https://doi.org/10.1093/glycob/cwm053
  25. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A (1988) Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 168: 1675-1684 https://doi.org/10.1084/jem.168.5.1675
  26. Scott P, Pearce E, Natovitz P, Sher A (1987) Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol 139: 221-227
  27. Souza MA, Afonso-Cardoso SR, Machado AP, Borges FAC, Lanza H, Pena JD (2004) The adjuvant effect of saponin (Quilara bark) in the vaccine against murine cutaneous leishmaniasis. Biosc J 20: 109-116
  28. Souza MA, Amâncio-Pereira F, Barros-Cardoso CR, Gomes- Silva A, Silva EG, Andrade LR, Pena JD, Lanza H, Afonso-Cardoso SR (2005) Isolation and partial characterization of a D-galactose-binding lectin from the látex of Synadenium carinatum. Braz Arch Biol Technol 48: 705- 716 https://doi.org/10.1590/S1516-89132005000600005
  29. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM (2004) Identification of a compensatory mutant (lpg2_REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun 72: 3622-3627 https://doi.org/10.1128/IAI.72.6.3622-3627.2004
  30. Stavnezer J (1996) Immunoglobulin class switching. Curr Opin Immunol 8: 199-205 https://doi.org/10.1016/S0952-7915(96)80058-6
  31. Teixeira CR, Cavassani KA, Gomes RB, Teixeira NJ, Roque- Barreira MC, Cavada BS, da Silva JS, Barral A, Barral- Netto M (2006) Potential of KM+ lectin in immunization against Leishmania amazonensis infection. Vaccine 24: 3001-3008 https://doi.org/10.1016/j.vaccine.2005.11.067
  32. World Health Organization Report (1998) Advances in battle against leishmaniasis. Tropical Disease Research News, no. 57